Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “In Expansion: Melanoma, Non-small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03504488
What this trial is testing

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Who this might be right for
Non Small Cell Lung CancerTriple Negative Breast CancerMelanoma+1 more
BioAtla, Inc. 132
Early research (Phase 1)Active Not RecruitingNCT05355701
What this trial is testing

Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Who this might be right for
MelanomaNon-Small-Cell Lung CancerThyroid Cancer+2 more
Pfizer 103
Early research (Phase 1)Ended earlyNCT03621982
What this trial is testing

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Who this might be right for
Head and Neck Cancer Squamous Cell CarcinomaNon-small Cell Lung CancerGastric Cancer+9 more
ADC Therapeutics S.A. 78
Testing effectiveness (Phase 2)Looking for participantsNCT05267626
What this trial is testing

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
Advanced Solid TumorMetastatic CancerCutaneous Melanoma+1 more
Aulos Bioscience, Inc. 159
Testing effectiveness (Phase 2)Study completedNCT05259696
What this trial is testing

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

Who this might be right for
OncologyMelanomaOvarian Cancer+14 more
Palleon Pharmaceuticals, Inc. 69
Testing effectiveness (Phase 2)Study completedNCT02437136
What this trial is testing

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

Who this might be right for
Non-Small Cell Lung CancerMelanomaMismatch Repair-Proficient Colorectal Cancer
Syndax Pharmaceuticals 191
Testing effectiveness (Phase 2)Looking for participantsNCT05592626
What this trial is testing

A Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsGenital Neoplasm, FemaleUrogenital Neoplasms+11 more
Marengo Therapeutics, Inc. 366
Testing effectiveness (Phase 2)Looking for participantsNCT07339176
What this trial is testing

Intratumoral N17350 in Advanced Solid Tumors

Who this might be right for
Neoplasms, Solid TumorBreast Neoplasms, Triple-NegativeSquamous Cell Carcinoma of Skin+4 more
Onchilles Pharma Inc 275
Early research (Phase 1)UnknownNCT04137900
What this trial is testing

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Who this might be right for
Advanced Unresectable Solid TumorMetastatic Solid Tumor
TopAlliance Biosciences 499
Testing effectiveness (Phase 2)Looking for participantsNCT07341737
What this trial is testing

SL-28 for Advanced Solid Tumours

Who this might be right for
Head & Neck CancerPancreas CarcinomaPancreas Cancer, Metastatic+15 more
Second Life Therapeutics 60
Early research (Phase 1)Ended earlyNCT06546553
What this trial is testing

Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

Who this might be right for
NeoplasmsNon-small-cell Lung CancerSquamous Cell Carcinoma of the Head and Neck+3 more
Pfizer 10
Early research (Phase 1)UnknownNCT05311618
What this trial is testing

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Who this might be right for
Pancreatic CancerBreast CancerGastric Cancer+13 more
NGM Biopharmaceuticals, Inc 71
Early research (Phase 1)Ended earlyNCT06448364
What this trial is testing

A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

Who this might be right for
Advanced or Metastatic Solid TumorsNon-Small Cell Lung CancerColorectal Cancer+2 more
Pfizer 4
Early research (Phase 1)Study completedNCT03761017
What this trial is testing

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Who this might be right for
Squamous Cell Non Small Cell Lung CancerProstate Cancer MetastaticCutaneous Melanoma+3 more
MacroGenics 162
Testing effectiveness (Phase 2)Study completedNCT04068896
What this trial is testing

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Who this might be right for
Pancreatic CancerMetastatic Castration-resistant Prostate CancerBladder Cancer+8 more
NGM Biopharmaceuticals, Inc 89
Early research (Phase 1)Ended earlyNCT02961283
What this trial is testing

Study of ASN003 in Subjects With Advanced Solid Tumors

Who this might be right for
NeoplasmsMelanomaColorectal Neoplasm+1 more
Asana BioSciences 24
Early research (Phase 1)Study completedNCT05479812
What this trial is testing

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

Who this might be right for
Metastatic Solid TumorAdvanced Solid Tumor
Werewolf Therapeutics, Inc. 156